Similar articles

• Bovine luteal cyclic AMP and cyclic GMP phosphodiesterase activity; sensitivity to various drugs and hormones.

  Goff AK, Major PW. Goff AK, et al. FEBS Lett. 1976 Jan 15;61(2):144-7. doi: 10.1016/0014-5793(76)81022-8. FEBS Lett. 1976. PMID: 174943 No abstract available.
• Partial purification of adenosine 3',5'-cyclic monophosphate phosphodiesterases from rat pancreas in the presence of excess protease inhibitors.

  Terai M, Furihata C, Matsushima T, Sugimura T. Terai M, et al. Arch Biochem Biophys. 1976 Oct;176(2):621-9. doi: 10.1016/0003-9861(76)90206-x. Arch Biochem Biophys. 1976. PMID: 185966 No abstract available.
• Morphone abstinence and quasi-abstinence effects after phosphodiesterase inhibitors and naloxone.

  Francis DL, Roy AC, Collier HO. Francis DL, et al. Life Sci. 1975 Jun 15;16(12):1901-6. doi: 10.1016/0024-3205(75)90299-4. Life Sci. 1975. PMID: 168452 No abstract available.
• Inhibitory and activators of cyclic nucleotide phosphodiesterase.

  Chasin M, Harris DN. Chasin M, et al. Adv Cyclic Nucleotide Res. 1976;7:225-64. Adv Cyclic Nucleotide Res. 1976. PMID: 188316 Review. No abstract available.
• Multiplicity within cyclic nucleotide phosphodiesterases.

  Rybalkin SD, Beavo JA. Rybalkin SD, et al. Biochem Soc Trans. 1996 Nov;24(4):1005-9. doi: 10.1042/bst0241005. Biochem Soc Trans. 1996. PMID: 8968501 Review. No abstract available.